Cumberland Pharmaceuticals (NASDAQ:CPIX) Releases Quarterly Earnings Results, Hits Estimates

Cumberland Pharmaceuticals (NASDAQ:CPIX) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13), FiscalAI reports. The firm had revenue of $9.13 million for the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a positive return on equity of 5.04% and a negative net margin of 6.37%.

Here are the key takeaways from Cumberland Pharmaceuticals’ conference call:

• Cumberland signed a transformational deal with Apotex to sell its U.S. branded commercial portfolio for $100 million cash plus $9 million for inventory, transition fees and a milestone, which management says will materially strengthen the balance sheet and fund a shift to a development-focused strategy.
• First‑quarter revenue from marketed brands was $9.1 million (up ~5% excluding a prior one‑time milestone), with a GAAP net loss of ~$3.3 million and an adjusted loss of $1.9 million ($0.13/share); operating cash flow was positive $387,000 and cash on hand was $11 million.
• The clinical pipeline, led by ifetroban, shows progress—~1,400 subjects dosed, FDA Fast Track plus Orphan/Rare Pediatric designations for Duchenne muscular dystrophy, completed enrollment in scleroderma, and ongoing IPF trials with an interim safety review clearing continuation and interim efficacy expected later this year.
• Commercial and manufacturing wins include FDA expanded labeling for Caldolor (post‑operative pain), FDA clearance of the manufacturing site enabling a planned Vaprisol relaunch this year, launch of Talicia sales promotion, and the first shipment of Vibativ to China—moves management says will broaden patient access prior to the portfolio sale.

Cumberland Pharmaceuticals Trading Up 0.4%

NASDAQ:CPIX traded up $0.02 during mid-day trading on Tuesday, reaching $4.55. 318,892 shares of the company’s stock traded hands, compared to its average volume of 787,554. Cumberland Pharmaceuticals has a 12-month low of $1.85 and a 12-month high of $6.26. The firm has a market capitalization of $68.07 million, a price-to-earnings ratio of -23.95 and a beta of -0.06. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.01 and a quick ratio of 0.84. The company has a 50 day moving average price of $3.45 and a 200-day moving average price of $3.42.

Analysts Set New Price Targets

A number of research analysts recently issued reports on CPIX shares. Wall Street Zen upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CPIX. XTX Topco Ltd purchased a new position in Cumberland Pharmaceuticals during the 2nd quarter valued at about $34,000. Bridgeway Capital Management LLC increased its holdings in Cumberland Pharmaceuticals by 2.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after purchasing an additional 4,200 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after acquiring an additional 27,980 shares during the period. Two Sigma Investments LP grew its holdings in shares of Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after acquiring an additional 5,326 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after acquiring an additional 5,653 shares during the period. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.